Vaxart, Inc. (NASDAQ:VXRT) Sees Significant Growth in Short Interest

Vaxart, Inc. (NASDAQ:VXRT) saw a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 13,280,000 shares, a growth of 17.0% from the February 13th total of 11,350,000 shares. Approximately 6.0% of the company’s shares are sold short. Based on an average trading volume of 1,960,000 shares, the short-interest ratio is presently 6.8 days.

Institutional Investors Weigh In On Vaxart

Hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC grew its stake in Vaxart by 15.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company’s stock valued at $2,160,000 after buying an additional 346,725 shares during the last quarter. Squarepoint Ops LLC grew its stake in shares of Vaxart by 95.0% in the fourth quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company’s stock valued at $342,000 after acquiring an additional 251,789 shares in the last quarter. Raymond James Financial Inc. bought a new position in Vaxart during the fourth quarter worth about $129,000. XTX Topco Ltd raised its stake in Vaxart by 869.3% in the 3rd quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company’s stock worth $116,000 after purchasing an additional 122,387 shares in the last quarter. Finally, Silverarc Capital Management LLC boosted its holdings in Vaxart by 7.8% in the 4th quarter. Silverarc Capital Management LLC now owns 1,077,782 shares of the biotechnology company’s stock valued at $714,000 after purchasing an additional 77,782 shares during the period. 18.05% of the stock is currently owned by institutional investors and hedge funds.

Vaxart Trading Down 2.8 %

Vaxart stock opened at $0.57 on Friday. The business has a 50-day moving average of $0.65 and a 200-day moving average of $0.71. The firm has a market capitalization of $129.14 million, a P/E ratio of -1.38 and a beta of 1.69. Vaxart has a 1 year low of $0.45 and a 1 year high of $1.41.

Vaxart (NASDAQ:VXRT) last released its quarterly earnings results on Thursday, March 20th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.05. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%. Research analysts anticipate that Vaxart will post -0.39 EPS for the current fiscal year.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.